Results 241 to 250 of about 229,451 (392)

Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide

BJU International, EarlyView.
Objectives To evaluate the longitudinal transcriptomic changes that occurred over time in patients from the ENACT trial (ClinicalTrials.gov identifier: NCT02799745). ENACT evaluated patients with low‐ or intermediate‐risk prostate cancer, comparing the efficacy and safety of enzalutamide plus active surveillance (AS) to AS alone.
Nicole Handa, Neal D. Shore, Matthew R. Cooperberg, Elai Davicioni, Xin Zhao, Dina Elsouda, Yang Liu, James A. Proudfoot, Gaston Kuperman, David Russell, Kenneth K. Iwata, Edward M. Schaeffer, Ashley Ross   +12 more
wiley   +1 more source

Efficacy of pain management for cattle castration: A systematic review and meta-analysis. [PDF]

Anim Welf
Nogues E, Stojkov J, Jonoska Stojkova B, von Keyserlingk MAG, Weary DM.   +4 more
europepmc   +1 more source

Community conversations on animal welfare [PDF]

, 2020
Demeke, Y., Doyle, R., Kumbe, A., Lemma, Mamusha, Mekonnen, Mesfin, Wieland, Barbara   +5 more
core  

PROLONGATION OF THE LIFE SPAN OF KOKANEE SALMON (ONCORHYNCHUS NERKA KENNERLYI) BY CASTRATION BEFORE BEGINNING OF GONAD DEVELOPMENT [PDF]

, 1961
O. H. Robertson
openalex   +1 more source

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

The Lancet, 2011
K. Fizazi, M. Carducci, Matthew R. Smith, R. Damião, Janet E Brown, L. Karsh, P. Milecki, N. Shore, M. Rader, Huei Wang, Q. Jiang, Sylvia Tadros, R. Dansey, C. Goessl   +13 more
semanticscholar   +1 more source

Preferences between three options for androgen deprivation therapy: a focus group study

BJU International, EarlyView.
Objectives Androgen deprivation therapy (ADT) forms the mainstay of treatment for advanced prostate cancer. Traditionally administered as a luteinising hormone‐releasing hormone (LHRH) agonist depot injection, newer options for ADT include transdermal oestradiol patches (tE2) or oral LHRH antagonists.
Hannah L. Rush, Sophie Merrick, John Marshall, John Deighan, Hoda Abdel‐Aty, Abdulla Alhasso, Noel W. Clarke, Roger Kockelbergh, Stephen Mangar, Stuart D. Rosen, Nicholas D. James, Duncan C. Gilbert, Annabelle South, Ruth E. Langley   +13 more
wiley   +1 more source

Summary of changes in the 2025 Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-resistant prostate cancer. [PDF]

Can Urol Assoc J
Saad F, So AI.
europepmc   +1 more source

Clinically relevant niclosamide concentrations modulate TMEM16A and CaV1.2 channels to control artery tone and capillary diameter

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose TMEM16A Ca2+‐gated Cl− channels mediate depolarisation of contractile vascular cells. The anthelmintic niclosamide was reported to modulate the TMEM16A channel, suggesting possible repurposing for vascular pharmacology. Here, we investigate the mechanism of TMEM16A modulation by niclosamide and explore its effect on the ...
Rachel Kaye, Claire Pearson, Tibyan Babiker, Emilio Agostinelli, Rumaitha Al‐Hosni, Paolo Tammaro   +5 more
wiley   +1 more source

Patient characteristics, treatment patterns, and survival outcomes in patients with castration-resistant prostate cancer: results from the J-CaP registry. [PDF]

Jpn J Clin Oncol
Onozawa M, Kawai T, Hinotsu S, Saito A, Mitomi T, Uno S, Kume H, Japan Study Group of Prostate Cancer (J-CaP).   +7 more
europepmc   +1 more source

MOUSE COMPLEMENT: THE EFFECT OF SEX HORMONES AND CASTRATION ON TWO OF THE LATE-ACTING COMPONENTS [PDF]

, 1967
W. Hallowell Churchill, Ronald M. Weintraub, Tibor Borsos, Herbert J. Rapp   +3 more
openalex   +1 more source